EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Switching to E-cigarettes as Harm Reduction Among Individuals With Chronic Disease Who Currently Smoke: Results of a Pilot Randomized Controlled Trial

Mahathi Vojjala iD, Elizabeth R Stevens iD, Andrew Nicholson, Tucker Morgan, Aayush Kaneria, Grace Xiang, Olivia Wilker, Rachel Wisniewski, Irina Melnic, Omar El Shahawy, Kenneth I Berger, Scott E Sherman

Nicotine and Tobacco Research · 2024

DOI: 10.1093/ntr/ntae158 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Nicotine and Tobacco Research, 2024. Verfasst von Mahathi Vojjala und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Population Health, NYU Grossman School of Medicine, New York, NY, USA. Hauptthemen laut MEDLINE: Electronic Nicotine Delivery Systems, Harm Reduction, Smoking Cessation. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: New York University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

E-cigarettes (ECs) may be an effective harm reduction strategy for individuals with conditions like chronic obstructive pulmonary disease (COPD), asthma, coronary artery disease (CAD), and peripheral arterial disease who smoke combustible cigarettes (CCs). Our aim was to examine how individuals with chronic conditions transition from CCs to ECs and its impact on health outcomes. Aims and Methods In a pilot randomized controlled trial (RCT), patients with COPD, asthma, and CAD/PAD who currently smoke CCs and have not used nicotine replacement therapy (NRT) or ECs in the past 14 days were randomized to receive ECs or combination NRT with behavioral counseling. Disease symptoms, acceptability/satisfaction (TSQM-9) and feasibility, and cigarettes per day (CPD), and/or EC use were collected at baseline, 3-, and 6 months. Descriptive statistics and a linear regression were conducted to explore changes in CPD and chronic condition-specific assessments (CAT, SAQ-7, and ACT) that assess COPD, asthma, and CAD/PAD symptom change.

Results

At 3 months, the EC group (n = 63, mean CPD = 9 ± 11) reduced their CPD by 54% versus 60% in the NRT group (n = 58, mean CPD = 7 ± 6), p = .56. At 6 months, 17.5% had switched completely to ECs while 23% quit smoking in the NRT arm. CAT scores showed a significant 6-point reduction in the EC arm (p = .03). Participants scored an average of 69 ± 27 for EC effectiveness, 87 ± 23 for convenience, and 75 ± 27 for overall satisfaction.

Conclusions

This pilot study suggests that ECs may be a safer alternative for chronic condition patients using CCs and warrants further research on expected smoking cessation/reduction among individuals who use ECs.

Implications

The findings from this pilot RCT hold significant implications for chronic conditions such as COPD, asthma, CAD, and peripheral arterial disease who smoke CCs. The observed reduction in CPD and improvement in respiratory symptoms suggest that switching to ECs appears feasible and acceptable among those with chronic diseases. These results suggest that ECs may offer an alternative for individuals struggling to quit CC smoking through existing pharmacotherapies. This study supports further exploration of switching to ECs as a harm reduction strategy among CC users who have been unsuccessful at quitting by other means.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Electronic Nicotine Delivery SystemsHarm ReductionSmoking CessationHumansPilot ProjectsFemaleMaleMiddle AgedChronic DiseaseAsthmaPulmonary Disease, Chronic ObstructiveAgedAdultTobacco Use Cessation DevicesVaping

Autor:innen und Institutionen

  • Department of Population Health, NYU Grossman School of Medicine, New York, NY, USA.
  • Department of Epidemiology, NYU School of Global Public Health, New York, NY, USA.
  • Department of Biostatistics, Columbia University Mailman School of Public Health, New York, NY, USA.
  • Department of Medicine, NYU Langone, New York, NY, USA.
  • Department of Medicine, VA New York Harbor Healthcare System, New York, NY, USA.

ORCID-Profile: Mahathi Vojjala, Elizabeth R Stevens

Förderung

  • New York University

Zitieren

APA

Vojjala, M., Stevens, E. R., Nicholson, A., Morgan, T., Kaneria, A., Xiang, G., Wilker, O., Wisniewski, R., Melnic, I., El Shahawy, O., Berger, K. I., & Sherman, S. E. (2024). Switching to E-cigarettes as Harm Reduction Among Individuals With Chronic Disease Who Currently Smoke: Results of a Pilot Randomized Controlled Trial. Nicotine and Tobacco Research. https://doi.org/10.1093/ntr/ntae158

Vancouver

Vojjala M, Stevens ER, Nicholson A, Morgan T, Kaneria A, Xiang G, et al. Switching to E-cigarettes as Harm Reduction Among Individuals With Chronic Disease Who Currently Smoke: Results of a Pilot Randomized Controlled Trial. Nicotine and Tobacco Research. 2024. doi:10.1093/ntr/ntae158

BibTeX
@article{Vojjala2024,
  author = {Vojjala, Mahathi and Stevens, Elizabeth R and Nicholson, Andrew and Morgan, Tucker and Kaneria, Aayush and Xiang, Grace and Wilker, Olivia and Wisniewski, Rachel and Melnic, Irina and El Shahawy, Omar and Berger, Kenneth I and Sherman, Scott E},
  title = {Switching to E-cigarettes as Harm Reduction Among Individuals With Chronic Disease Who Currently Smoke: Results of a Pilot Randomized Controlled Trial},
  journal = {Nicotine and Tobacco Research},
  year = {2024},
  doi = {10.1093/ntr/ntae158}
}
Kostenlos starten →